Company Information
- Type:
- Company
- Country:
- United States of America
- Sector:
- Pharmaceuticals & Biotechnology
- Ownership:
- Publicly Listed
- Global Compact Status:
- Delisted
- Reason for Delisting:
- Expelled due to failure to communicate progress
- Participant Since
- 06 May 2009 Letter of Commitment
- Next Communication on Progress (COP) due on:
- 16 September 2020
Financial Information
Communication On Progress
| Published On | Title | Level/Status |
|---|---|---|
| 16-Sep-2019 | Communication on Progress 2019 | Active |
| 24-Sep-2018 | Communication on Progress 2018 | Active |
| 25-Sep-2017 | Communication on Progress | Active |
| 28-Sep-2016 | Communication on Progress | Active |
| 29-Jun-2016 | Grace Letter | Not applicable |
| 20-Apr-2016 | Reporting Cycle Adjustment | Not applicable |
| 24-Apr-2015 | Communication on Progress | Active |
| 24-Apr-2014 | Allergan's UNGC Communication on Progress | Active |
| 26-Apr-2013 | 2013 Allergan’s UN Global Compact Communication on Progress | Active |
| 26-Apr-2012 | 2012 Allergan Communication on Progress | Active |
| 02-May-2011 | 2011 Allergan Communication on Progress | Active |
| 02-May-2011 | 2011 Allergan Communication on Progress | Active |
Note: Responsibility for the content of participants' public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact.
Note on levels: Not applicable refers to the period when the Communication on Progress (CoP) did not require differentiation levels. With the new CoP, for the 2022 Early Adopter Programme, and for 2023, there will be no differentiation levels.